A Comparison of Patient Adherence and Preference of Packaging Method for Oral Anticancer Agents Using Conventional Pill Bottles versus Daily Pill Boxes

ISRCTN ISRCTN74558413
DOI https://doi.org/10.1186/ISRCTN74558413
Secondary identifying numbers N/A
Submission date
08/11/2005
Registration date
15/11/2005
Last edited
24/07/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Lillian Siu
Scientific

Princess Margaret Hospital
610 University Avenue
Toronto
M5G 2M9
Canada

Phone +1 416 946 2911
Email lillian.siu@uhn.on.ca

Study information

Study designRandomized cross-over design
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Scientific title
Study objectivesWe hypothesize that a simple, low-tech assistance device, such as daily pill boxes, as compared to conventional pill bottles, will increase the rate of patientsÂ’ adherence to oral chemotherapy.
Ethics approval(s)UHN Research Ethics Board, 02/05/2005, UHN REB 05-0199-CE
Health condition(s) or problem(s) studiedAdvanced solid tumors
InterventionDaily pill boxes versus conventional pill bottles for packaging
Intervention typeOther
Primary outcome measurePatient adherence was similiar.
Secondary outcome measuresPatients more satisfied with daily pill boxes than conventional pill bottles.
Overall study start date01/04/2005
Completion date30/06/2005

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants25
Key inclusion criteriaPatients were included in this study if they:
1. Provided informed consent
2. Were capable of reading and writing in English
3. Were greater than 18 years of age with solid tumors
4. Were planned to receive at least 2 consecutive cycles of capecitabine
Key exclusion criteriaPatients taking other oral anticancer medications such as temozolomide, tamoxifen and arimidex, were not felt to be suitable for the present study since these oral medications are already dispensed in unit dose packages.
Date of first enrolment01/04/2005
Date of final enrolment30/06/2005

Locations

Countries of recruitment

  • Canada

Study participating centre

Princess Margaret Hospital
Toronto
M5G 2M9
Canada

Sponsor information

Princess Margaret Hospital (Canada)
Hospital/treatment centre

610 University Avenue
Toronto
M5G 2M9
Canada

Phone +1 416 946 2911
Email lillian.siu@uhn.on.ca
ROR logo "ROR" https://ror.org/03zayce58

Funders

Funder type

Hospital/treatment centre

Dr Lillian Siu's research funds

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/07/2007 Yes No